ConductScience.org, home

Comparison · NCT02495467-fb8e37b4

MED2005 vs MED Placebo: Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. MED2005 vs MED Placebo: Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2. Trial comparisons, record NCT02495467-fb8e37b4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02495467-fb8e37b4

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3940.3310.46wilson
Risk in group 20.250.1970.312wilson
Risk difference, group 1 minus group 20.1440.05550.229newcombe hybrid score
Risk ratio, group 1 over group 21.571.182.09log
Odds ratio, group 1 over group 21.951.292.94log
Number needed to treat, for one more participant with the outcome on MED2005 than on MED Placebo6.974.3818from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1MED2005Participants who received MED2005 (0.2% glyceryl trinitrate gel). At least 4 applications of MED2005 prior to intercourse in either the first or last 4 weeks of the study.85216OG001
Group 2MED PlaceboParticipants who received MED Placebo. At least 4 applications of MED Placebo prior to intercourse in either the first or last 4 weeks of the study.54216OG000

Outcome

Type
SECONDARY
Title
Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2
Description
GAQ Question 2: Has the treatment improved your ability to engage in sexual activity?. Answered yes/no after each treatment period of 4 weeks (+/- 1 week).
Time frame
4 Weeks
Population
Full Analysis Set. A total of 230 subjects reported at least one intercourse attempt and had at least one IIEF assessment in a period for which at least one intercourse attempt was reported. Complete cases only.

Source ClinicalTrials.gov

Trial

Title
Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)
NCT number
NCT02495467
Phases
PHASE2
Conditions
Erectile Dysfunction
Interventions
Glyceryl trinitrate, MED Placebo
Lead sponsor
Futura Medical Developments Ltd.
Results first posted
2020-01-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02495467-fb8e37b4